PMID- 1503912
OWN - NLM
STAT- MEDLINE
DCOM- 19920921
LR  - 20220408
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 66
IP  - 2
DP  - 1992 Aug
TI  - Prognostic implications of p53 protein, epidermal growth factor receptor, and 
      Ki-67 labelling in brain tumours.
PG  - 373-85
AB  - The expression of p53 protein, epidermal growth factor receptor (EGFR), and Ki-67 
      nuclear antigen was examined by immunohistochemistry in biopsies of 16 types of 
      human brain tumours, including 43 astrocytomas. P53 protein, almost certainly its 
      mutant form, was expressed in seven of the 16, and EGFR in 11 of the 16 types of 
      tumours. In astrocytomas both the proportion of tumours which expressed p53 or 
      EGFR increased with grade of malignancy as did the mean Ki-67 labelling index 
      (LI): p53-0% in grade 1, 17% in grade 2, 38% in grade 3, 65% in grade 4; EGFR-0% 
      in grade 1, 33% in grade 2, 85% in grade 3, 95% in grade 4; mean Ki-67 L1-1.1% in 
      grades 1 and 2, 8.3% in grade 3, and 13.4% in grade 4. Astrocytomas which 
      expressed p53 or EGFR had a significantly higher Ki-67 LI at P less than 0.05 
      (11.8% and 10.7%, resp.) than those that did not (6.2% or 4.1%, resp.). Patients 
      with astrocytomas expressing p53 or EGFR had a significantly reduced survival (P 
      = 0.035 and P = 0.007, resp.): only 11% of the p53 + ve and 13% of the EGFR + ve 
      patients were alive at 100 weeks following diagnosis compared to 36% of p53-ve or 
      60% of EGFR-ve patients. Patients with Ki-67 LI greater than 5% had a reduced 
      survival (P less than 0.0001)--none survived beyond 86 weeks following diagnosis, 
      whilst 63% of patients with less than 5% positive cells were still alive at 100 
      weeks. The univariate analysis showed that in astrocytomas expression of p53 
      mutants, EGFR protein, and Ki-67 greater than 5% are associated with malignant 
      progression and poor prognosis. The multivariate analysis revealed that only 
      tumour grade and Ki-67LI were independent prognostic factors for survival.
FAU - Jaros, E
AU  - Jaros E
AD  - Department of Neuropathology, Newcastle General Hospital, Newcastle upon Tyne, 
      UK.
FAU - Perry, R H
AU  - Perry RH
FAU - Adam, L
AU  - Adam L
FAU - Kelly, P J
AU  - Kelly PJ
FAU - Crawford, P J
AU  - Crawford PJ
FAU - Kalbag, R M
AU  - Kalbag RM
FAU - Mendelow, A D
AU  - Mendelow AD
FAU - Sengupta, R P
AU  - Sengupta RP
FAU - Pearson, A D
AU  - Pearson AD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Astrocytoma/*pathology
MH  - Biomarkers, Tumor/*analysis
MH  - Biopsy
MH  - Brain Neoplasms/*pathology
MH  - Child
MH  - Child, Preschool
MH  - ErbB Receptors/*analysis
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunohistochemistry
MH  - Karyotyping
MH  - Ki-67 Antigen
MH  - Male
MH  - Middle Aged
MH  - Nuclear Proteins/*analysis
MH  - Regression Analysis
MH  - Time Factors
MH  - Tumor Suppressor Protein p53/*analysis
PMC - PMC1977794
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
AID - 10.1038/bjc.1992.273 [doi]
PST - ppublish
SO  - Br J Cancer. 1992 Aug;66(2):373-85. doi: 10.1038/bjc.1992.273.